Life Sciences News | BioTuesdays by Kilmer Lucas IR

Developments

Endologix gets CE Mark for ALTO abdominal stent graft system

Endologix (NASDAQ:ELGX) received a CE Mark for its ALTO abdominal stent graft system. ALTO is an endovascular aneurysm repair device designed to increase patient applicability and technical success rate, and improve...

August 5, 2020

Developments

Axsome AXS-12 gets FDA breakthrough therapy designation for narcolepsy

The FDA granted Axsome Therapeutics’ (NASDAQ:AXSM) AXS-12 breakthrough therapy designation for the treatment of cataplexy in patients with narcolepsy. Narcolepsy is a neurological condition characterized by excessive...

August 5, 2020

Developments

DBV Technologies gets FDA complete response letter for Viaskin Peanut

The FDA issued DBV Technologies (NASDAQ:DBVT) a complete response letter (CRL) regarding the company’s BLA for Viaskin Peanut, and epicutaneous patch to treat peanut allergies in children. The FDA identified concerns...

August 5, 2020

Developments

Eloxx Pharma ELX-02 granted FDA orphan drug designation for cystic fibrosis

Eloxx Pharmaceuticals’ (NASDAQ:ELOX) ELX-02 received FDA orphan drug designation for the treatment of cystic fibrosis (CF). ELX-02 is a small molecule designed to restore production of CF transmembrane conductance...

August 5, 2020

Developments

Hepion doses first patient with CRV431 in Phase 2 NASH study

Hepion Pharmaceuticals (NASDAQ:HEPA) dosed the first patient in its Phase 2 trial assessing CRV431 for the treatment of non-alcoholic steatohepatitis (NASH). The Phase 2a study, called AMBITION, is designed to assess...

August 5, 2020

Markets

WB starts Beam Therapeutics at OP; fair value estimate $33

William Blair initiated coverage of Beam Therapeutics (NASDAQ:BEAM) with an “outperform” rating and $33 fair value estimate. The stock closed at $19.01 on Aug. 4. Beam is focused on base editing, a next-generation gene...

August 5, 2020

Markets

WB starts Poseida Therapeutics at OP; fair value estimate $39

William Blair launched coverage of Poseida Therapeutics (NASDAQ:PSTX) with an “outperform” rating and fair value estimate of $39. The stock closed at $12.98 on Aug. 3. “In our view, Poseida’s broad suite of platform...

August 4, 2020

Markets

HCW starts Lumos Pharma at buy; PT $33

H.C. Wainwright initiated coverage of Lumos Pharma (NASDAQ:LUMO) with a “buy” rating and $33 price target. The stock closed at $13.80 on Aug. 3. Analyst Edward White writes that the company’s LUM-201 drug candidate is...

August 4, 2020

Markets

Stifel starts Nkarta at buy; PT $41

Stifel launched coverage of Nkarta (NASDAQ:NKTX) with a “buy” rating and 12-month target price of $41. The stock closed at $26.58 on Aug. 3. Nkarta is focused on the discovery, development, and potential...

August 4, 2020

Markets

Stifel starts Geron at buy; PT $3

Stifel initiated coverage of Geron (NASDAQ:GERN) with a “buy” rating and $3 price target. The stock closed at $1.59 on July 31. Geron is focused on the development and potential commercialization of a single product...

August 3, 2020

Markets

Raymond James cuts Cardiol Therapeutics to market perform; PT to $3.50 from $4.50

Raymond James downgraded Cardiol Therapeutics (TSX:CRDL) to “market perform 3” from “outperform 2” and reduced its price target to $3.50 (Canadian) from $4.50, citing continued delays in the commercial launch of...

August 3, 2020

Executive Moves

Zenabis names Shai Altman as president and CEO

Shai Altman Zenabis Global (TSX:ZENA) appointed Shai Altman as president and CEO, effective September 1. Mr. Altman will replace interim CEO, Kevin Coft, who will return to his role as Zenabis’ chief...

July 31, 2020

Subscribe